Most prostate cancers are initially androgen-dependent (AD) and are generally treated with a combination of radiotherapy, chemical castration, androgen-receptor (AR) antagonists (hydroxyflutamide, bicalutamide), or inhibitors of steroidogenesis (abiraterone). The gene discussed is AR; the disease is prostate cancer.